SCHEMBL5831323

SCHEMBL5831323

O=[N+]([O-])c1ccc(Cl)c(-c2nnc(NS(=O)(=O)c3ccc(-c4ccccc4)cc3)s2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.57
KMT2A Q03164 7/20 0.57
LMNA P02545 2/20 0.57
ALOX12 P18054 2/20 0.57
HTT P42858 2/20 0.57
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
AMY1A P0DUB6 1/20 0.49
POLB P06746 1/20 0.49
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM1A O60341 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831014 0.83 MEN1 (0.68) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5831564 0.83 POLB (0.48) MEN1KMT2ALMNAALOX12HTT
SCHEMBL2197860 0.82 MEN1 (0.70) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5831263 0.82 FSCN1 (0.47) MEN1KMT2ALMNAALOX12HTT
SCHEMBL2762577 0.82 MEN1 (0.70) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5831396 0.82 MEN1 (0.50) MEN1KMT2ALMNAALOX12HTT
SCHEMBL6610921 0.80 CRHBP (0.58) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5830908 0.80 AMY1A (0.50) MEN1KMT2ALMNAHTTAMY1A
SCHEMBL5830748 0.78 FSCN1 (0.43) MEN1KMT2AAMY1AALDH1A1HPGD
SCHEMBL6613680 0.77 CRHBP (0.57) MEN1KMT2ALMNAALOX12HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 MEN1 903/4885KMT2A 2980/4885LMNA 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.